Centessa IPO Presentation Deck

IP ADDRESS. 51.89.224.65 TA and Modality Agnostic Programs with Clear Biological Rationale Palladio Biosciences ApcinteX Pega-One Z Factor Morphogen-IX ROADSHOW Capella BioScience IP ADDRESS 51.80.224.05 LockBody Orexia Therapeutics Janpix Pearl River Bio Therapeutic Area (TA) Nephrology Autosomal Dominant Polycystic Kidney Disease Hemophilia A, B Cutaneous Squamous Cell Carcinoma Alpha-1 Antitrypsin Deficiency Pulmonary Arterial Hypertension Idiopathic Pulmonary Fibrosis Systemic Sclerosis & Lupus Erythematosus Solid TumorsNTING, COPYING Narcolepsy Type 1 Acute Myeloid Leukemia NSCLC Hematology Oncology DISCOVERY Vasopressin V2 Receptor Inhibitor (Lixivaptan) Activated Protein C Inhibitor (Serpin PC) Anti-EGFR mAb (Imgatuzumab) Lead A1AT Folding Corrector (ZF874) A1AT Folding Corrector (ZF887) BMP9 Engineered Variant (MGX292) Anti-LIGHT mAb (CB5001) Anti-BDCA-2 mAb (CBS004) CD47 LockBody (LB1) CD3 LockBody (LB2) OX2R Agonist (Oral) OX2R Agonist (Intranasal) Dual-STAT3/5 Degrader EGFR-Ex20 Inhibitor EGFR-C7975 Inhibitor EGFR-Next Gen Hepatology LEAD OP/IND-ENABLING Pulmonology IS AND DISTRIBUTION OF Immunology/Inflammation CONF TIAL PHASE 1 IP ADDRESS 51.89.224.65 Neuroscience Reason to Believe in Target PHASE 2 PHASE 3 PRINTING, COPYING AND DISTRIBUTION OF ROADSHOW MATERIALS IS STRICTLY PROHIBIT Precedented Human Activity SHOW MATERIALS IS STRICTLY PROHIBIT Human Genetics 18 CENTESSA

View entire presentation